E

    Elicio Therapeutics Inc. (ELTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.70
    -0.14 (-4.93%)

    Market Cap: $70.96M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(6/16)
    Avg Surprise
    -17.42%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.44
    Range$-0.48 - $-0.40
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.43+2.3%
    60d ago$-0.50-13.1%
    30d ago$-0.47-7.4%
    7d ago$-0.47-7.4%
    Current$-0.44
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.51
    Range$-0.73 - $-0.39
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.51---
    Sep 26EST
    		-$-0.44---
    Jun 26
    Reported Aug 6
    		$-0.43$-0.53+18.87%Beat+34.8%
    Mar 26
    Reported May 11
    		$-0.65$-0.46-41.30%Miss+25.3%
    Dec 25
    Reported Mar 12
    		$-0.49$-0.45-10.11%Miss+52.0%
    Sep 25
    Reported Nov 13
    		$-0.60$-0.48-25.00%Miss+56.8%
    Jun 25
    Reported Aug 7
    		$-0.66$-0.69+4.35%Beat-3.1%
    Mar 25
    Reported May 13
    		$-0.87$-0.83-4.82%Miss+24.3%
    Dec 24
    Reported Mar 31
    		$-1.02$-0.88-16.57%Miss+41.7%
    Sep 24
    Reported Nov 13
    		$-1.39$-0.73-90.41%Miss-9.4%
    Jun 24
    Reported Aug 13
    		$-0.64$-0.96+33.33%Beat+73.7%
    Mar 24
    Reported May 15
    		$-1.15$-1.09-5.50%Miss+23.7%
    Dec 23
    Reported Feb 13
    		$-1.75$-0.78-124.36%Miss+16.7%
    Sep 23
    Reported Nov 9
    		$-1.27$-0.80-58.75%Miss+57.7%
    Jun 23
    Reported Aug 11
    		$-2.44$0.00N/ABeat+18.7%
    Mar 23
    Reported May 10
    		$-1.51$0.00N/ABeat+68.6%
    Dec 22
    Reported Mar 29
    		$-2.10$-2.10+0.00%Beat+60.1%
    Sep 22
    Reported Nov 14
    		$-3.00$-3.60+16.67%Beat-566.7%
    Jun 22
    Reported Aug 16
    		$-3.00$-4.63+35.21%Beat+80.8%
    Mar 22
    Reported Jun 29
    		$-4.80$-4.35-10.34%Miss-
    Sep 21
    Reported Nov 12
    		$-5.26N/AN/ABeat-
    Jun 21
    Reported Sep 28
    		$-0.45$0.00N/AMiss-
    Mar 21
    Reported Jun 29
    		$-15.65N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.24EV/EBITDA-2.61x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-775.00%ROIC-167.09%
    Financial Health
    Debt/Equity1.20xInterest Coverage-23.39x
    Current Ratio2.77xQuick Ratio2.77x
    Trading Statistics
    Beta1.88Avg Volume276.54K
    52-Week High$16.0052-Week Low$2.66

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.99
    SMA 20$3.05
    SMA 50$3.25
    SMA 200$8.15
    EMA 10$2.94
    EMA 20$3.05
    EMA 50$4.10
    EMA 200$7.28

    MACD

    Line: -0.22Signal: -0.26Hist: 0.04

    ADX

    ADX: 11.6+DI: 19.2-DI: 28.6

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down100.0
    PSAR$4.23

    Bollinger Bands

    Upper Band$3.29
    Lower Band$2.81
    %B Position1552%(Upper)
    Band Width-0.24

    RSI (14-Day)

    Neutral
    33.3

    Momentum Oscillators

    Stoch %K4.8
    Stoch %D8.7
    Williams %R-100.0
    ROC (10d)-10.6%
    Momentum-0.32
    CCI (20d)-278.3
    MFI (14d)38.0

    Volatility Measures

    ATR (14d)$0.22(8.2%)
    StdDev (20d)0.12
    Hist Vol53.9%(High)

    Volume Flow

    VWAP$2.76
    OBV33.8M
    AD Line-18.9M
    CMF (20d)-0.217

    Volume Metrics

    Avg Vol (20d)275.7K
    Vol Ratio1.5x
    VWMA (20d)$3.04

    Pivot Points

    R3$3.11
    R2$3.05
    R1$2.95
    Pivot Point$2.89
    S1$2.79
    S2$2.73
    S3$2.63

    Advanced Oscillators

    TSI-22.31
    Ultimate Osc23.4
    KST-47.58

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.17M$0$0$0$0$0
    Cost of Revenue$0$0$286,000$0$0$0$305,000$0$0$0$286,000$0
    Gross Profit$0$0$-286,000$0$0$0$-305,000$0$0$0$-286,000$0
    Operating Expenses$10.43M$10.60M$8.84M$8.04M$10.09M$10.74M$13.48M$10.34M$10.92M$10.24M$9.39M$10.77M
    R&D$6.81M$6.76M$5.08M$5.04M$7.01M$7.78M$10.71M$7.21M$8.18M$7.56M$6.16M$7.26M
    SG&A$3.62M$3.85M$3.76M$3.01M$3.08M$2.96M$2.77M$3.14M$2.74M$2.68M$3.23M$3.51M
    Operating Income$-10,429,000$-10,602,000$-8,842,000$-8,045,000$-10,091,000$-10,736,000$-13,477,000$-10,344,000$-10,924,000$-10,241,000$-9,392,000$-10,771,000
    Interest Income$138,000$157,000$199,000$199,000$168,000$210,000$305,000$185,000$137,000$150,000$78,000$246,000
    Interest Expense$410,000$407,000$337,000$426,000$194,000$176,000$233,000$137,000$49,000$36,000$1,000$1,000
    Income Before Tax$-8,217,000$-11,823,000$-7,718,000$-10,083,000$-10,561,000$-11,209,000$-14,004,000$-18,838,000$-7,229,000$-11,827,000$-9,054,000$-10,553,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-8,217,000$-11,823,000$-7,718,000$-10,083,000$-10,561,000$-11,209,000$-14,004,000$-18,838,000$-7,229,000$-11,827,000$-8,949,000$-10,658,000
    EBITDA$-7,556,000$-11,262,000$-7,112,000$-9,573,000$-10,254,000$-10,930,000$-13,722,000$-18,570,000$-7,024,000$-11,654,000$-8,845,000$-10,525,000
    EBIT$-7,945,000$-11,573,000$-7,580,000$-9,856,000$-10,535,000$-11,243,000$-14,076,000$-18,886,000$-7,317,000$-11,944,000$-9,131,000$-10,798,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ELTX

    News

    Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

    Elicio Therapeutics will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. CEO Robert Connelly and CSO Pete DeMuth, PhD, will discuss the company's progress in developing next-generation immunotherapies for KRAS-driven cancers. The clinical-stage biotechnology company focuses on off-the-shelf immunotherapies, including its lead program ELI-002 7P targeting common KRAS mutations.

    The Manila Times•8/31/26•
    Neutral

    Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

    Elicio Therapeutics, Inc. announced its participation in the Wells Fargo 21st Annual Healthcare Conference, where management will hold one-on-one meetings. The clinical-stage biotechnology company, focused on next-generation immunotherapies for KRAS-driven cancers, will be represented at the event taking place from September 8-10, 2026, in Boston, MA. Interested parties can arrange meetings through their Wells Fargo representative.

    Yahoo Finance•8/25/26•
    Somewhat-Bullish

    Pomerantz investigates Elicio Therapeutics after Phase 2 trial failure

    Pomerantz LLP is investigating Elicio Therapeutics for potential securities fraud after its Phase 2 AMPLIFY-7P Study for adjuvant pancreatic cancer failed to meet its primary endpoint of disease-free survival. This announcement on June 15, 2026, led to a 70.96% drop in Elicio's stock price. Investors are encouraged to contact Pomerantz LLP to discuss their legal rights following this significant financial impact.

    scanx.trade•8/24/26•
    Bearish

    Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

    Elicio Therapeutics, a clinical-stage biotechnology company focused on immunotherapies for KRAS-driven cancers, announced its participation in the Wells Fargo 21st Annual Healthcare Conference. Management will hold one-on-one meetings on September 10, 2026, to discuss the company's progress and pipeline, including its lead ELI-002 7P program.

    The Manila Times•8/24/26•
    Somewhat-Bullish

    Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

    Elicio Therapeutics, Inc. announced its participation in the Wells Fargo 21st Annual Healthcare Conference, where management will hold one-on-one meetings. The company, a clinical-stage biotechnology firm, focuses on developing next-generation immunotherapies for KRAS-driven cancers. This includes their lead program ELI-002 7P, an off-the-shelf immunotherapy candidate targeting common KRAS mutations.

    GlobeNewswire•8/24/26•
    Somewhat-Bullish

    Frequently Asked Questions About ELTX

    Does ELTX pay dividends?
    Elicio Therapeutics Inc. (ELTX) does not currently pay a regular dividend.
    What is ELTX's market cap?
    Elicio Therapeutics Inc. (ELTX) has a market capitalization of $70.96M with a current stock price of $2.70.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In